News >

Novel Drug Combination Shows Early Activity in Microsatellite Stable CRC

Kristi Rosa
Published: Friday, Nov 16, 2018

The novel immunomodulatory agent pixatimod (PG545) in combination with the PD-1 inhibitor nivolumab (Opdivo) may benefit patients with advanced bowel cancers, including a small subset of those with colorectal cancer (CRC) considered to be microsatellite stable (MSS), according to early results from a phase Ib trial.

“Although these are results from just a small number of patients, the effect of this drug combination on a cancer subtype known to be inherently resistant to immune checkpoint inhibitors suggest that pixatimod may boost the effectiveness of nivolumab by providing another signal to the immune system, alerting it to these cancers,” Ribas said.
Kuo J, Bampton, D, Lemech, CR, et al. Preliminary results from a phase 1b study of pixatimod (PG545) in combination with nivolumab in patients with advanced solid tumors with an expansion cohort in patients with metastatic pancreatic cancer. In: Proceedings from the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; November 13-16, 2018; Dublin, Ireland. Abstract 9. https://bit.ly/2zZtFBp.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x